* TherapeuticsMD Inc TXMD.OQ TXMD.O is expected to show
a rise
in quarterly revenue when it reports results on November 9
(estimated).
* The Boca Raton Florida-based company is expected to
report a
5.5% increase in revenue to $26.8 million from $25.41 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for TherapeuticsMD Inc
is for
a loss of 57 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for
TherapeuticsMD
Inc is $65, above its last closing price of $5.28.
This summary was machine generated November 7 at 14:38 GMT. All
figures in US dollars unless otherwise stated